People

Search Language

中文(台灣) / Traditional Chinese | Use language selector above (below, on mobile) to search additional languages
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  • Search
  • Selected filters
  • x(Public Sector)

1358 items matching filters

Search Results

Orrick partner Josh Rosenkranz

Practice:

  • Finance Sector
  • Supreme Court and Appellate
  • Intellectual Property
  • Complex Litigation & Dispute Resolution
  • White Collar, Investigations, Securities Litigation & Compliance
  • Antitrust & Competition
  • Life Sciences & HealthTech

E. Joshua Rosenkranz Partner

New York

Josh has been named American Lawyer's “Litigator of the Year” twice, in addition to being a finalist for 2022 and 2025. In 2012, the magazine dubbed him “the Defibrillator” based on his streak of appellate wins for companies that “appeared to be at death’s door,” and in 2017 it declared, he “still deserves the moniker we once gave him.”

In 2014, The Financial Times named Josh one of the 10 most innovative lawyers in the North American legal sector for his work “demystify[ing] the technical issues” and securing a victory in the blockbuster Federal Circuit appeal, Oracle v. Google. Chambers USA has reported, “He wins accolades for his ‘brilliant analysis and judgment.’ Clients appreciate how he ‘rethinks every case from the ground up,’ and add: ‘He can take the most complicated legal or technological issue and present it in a way that seems like common sense.’” Another edition of Chambers USA added: “‘His briefs are quite simply beautiful,’” and “clients describe his courtroom presence as ‘both commanding and accessible at the same time.’ He has the ‘perfect combination of persuasiveness, intelligence, wit, and deference.’”

Josh's practice covers a wide range of subjects, including intellectual property, financial services, securities, privacy, antitrust, federal preemption, insurance law, corporate governance, criminal law, and constitutional litigation. Among his recent clients are Cisco, Credit Suisse, Cox Communications, DISH Network, Genentech, Gilead, Johnson & Johnson, JPMorgan Chase, Microsoft, Mozilla, Oracle, Sonos, and Royal Bank of Scotland.

Clients turn to Josh to win the highest stakes appeals, including appeals in cases that threaten the very survival of a business. For example:

  • He represented Microsoft in an international cause célèbre in the U.S. Supreme Court challenging the U.S. Government’s claim that it can serve warrants for emails stored overseas.
  • He represented DISH Network in one of the most high-profile patent appeals in the country, successfully overturning an injunction that threatened the company's life.
  • He has been lead counsel in multiple cases either defending or challenging verdicts over $1 billion.
  • He represented Facebook in the high-profile battle waged by the founder's Harvard classmates, the Winklevoss twins, who laid claim to the idea for Facebook, winning a ruling from the Ninth Circuit to end the lawsuit.
  • He won a landmark victory in a Supreme Court case that rescued the estimated $60 billion U.S. market of copyrighted goods manufactured abroad.
  • He represented 36 law schools in a high-profile Supreme Court case against the Department of Defense.

Josh was the founding president and CEO of the Brennan Center for Justice at New York University School of Law, one of the country’s foremost public interest firms. Over the course of eight years, he was the Brennan Center’s chief strategist on litigation and public policy advocacy. Before that, Josh founded the Office of the Appellate Defender, a public defender office specializing in criminal appeals.

Orrick partner Josh Rosenkranz

Practice:

  • Finance Sector
  • Supreme Court and Appellate
  • Intellectual Property
  • Complex Litigation & Dispute Resolution
  • White Collar, Investigations, Securities Litigation & Compliance
  • Antitrust & Competition
  • Life Sciences & HealthTech

E. Joshua Rosenkranz Partner

New York

Josh has been named American Lawyer's “Litigator of the Year” twice, in addition to being a finalist for 2022 and 2025. In 2012, the magazine dubbed him “the Defibrillator” based on his streak of appellate wins for companies that “appeared to be at death’s door,” and in 2017 it declared, he “still deserves the moniker we once gave him.”

In 2014, The Financial Times named Josh one of the 10 most innovative lawyers in the North American legal sector for his work “demystify[ing] the technical issues” and securing a victory in the blockbuster Federal Circuit appeal, Oracle v. Google. Chambers USA has reported, “He wins accolades for his ‘brilliant analysis and judgment.’ Clients appreciate how he ‘rethinks every case from the ground up,’ and add: ‘He can take the most complicated legal or technological issue and present it in a way that seems like common sense.’” Another edition of Chambers USA added: “‘His briefs are quite simply beautiful,’” and “clients describe his courtroom presence as ‘both commanding and accessible at the same time.’ He has the ‘perfect combination of persuasiveness, intelligence, wit, and deference.’”

Josh's practice covers a wide range of subjects, including intellectual property, financial services, securities, privacy, antitrust, federal preemption, insurance law, corporate governance, criminal law, and constitutional litigation. Among his recent clients are Cisco, Credit Suisse, Cox Communications, DISH Network, Genentech, Gilead, Johnson & Johnson, JPMorgan Chase, Microsoft, Mozilla, Oracle, Sonos, and Royal Bank of Scotland.

Clients turn to Josh to win the highest stakes appeals, including appeals in cases that threaten the very survival of a business. For example:

  • He represented Microsoft in an international cause célèbre in the U.S. Supreme Court challenging the U.S. Government’s claim that it can serve warrants for emails stored overseas.
  • He represented DISH Network in one of the most high-profile patent appeals in the country, successfully overturning an injunction that threatened the company's life.
  • He has been lead counsel in multiple cases either defending or challenging verdicts over $1 billion.
  • He represented Facebook in the high-profile battle waged by the founder's Harvard classmates, the Winklevoss twins, who laid claim to the idea for Facebook, winning a ruling from the Ninth Circuit to end the lawsuit.
  • He won a landmark victory in a Supreme Court case that rescued the estimated $60 billion U.S. market of copyrighted goods manufactured abroad.
  • He represented 36 law schools in a high-profile Supreme Court case against the Department of Defense.

Josh was the founding president and CEO of the Brennan Center for Justice at New York University School of Law, one of the country’s foremost public interest firms. Over the course of eight years, he was the Brennan Center’s chief strategist on litigation and public policy advocacy. Before that, Josh founded the Office of the Appellate Defender, a public defender office specializing in criminal appeals.

Practice:

  • Mergers & Acquisitions

Ramy Shweiky Partner

San Francisco

Ramy advises public and private companies and their financial sponsors in the technology and life sciences sectors on complex, strategic transactions, including cross-border M&A, joint ventures, and multi-jurisdictional carve-outs. He also counsels boards and investors on fiduciary duties and other corporate governance matters.

Ramy is a member of the board of directors of Crisis Text Line, a global not-for-profit organization providing free mental health texting service. He has been recognized as a "Rising Star" in M&A by Super Lawyers.

Select Transactions

  • Workday in connection with multiple transactions, including its pending acquisitions of Sana Labs and Paradox, and its acquisitions of Flowise, Evisort, HiredScore, VNDLY, Peakon and Zimit.
  • Trimble in connection with its sale of Spatial Dimension to an affiliate of Vela Software, its global divestment of four businesses to The Jordan Company, and its acquisition of several software companies, including: StructShare, Bilberry, Azteca Systems LLC (dba “Cityworks”); Vianova Systems AS; Nexala Ltd.; Manhattan Software Group Ltd.; and certain other confidential non-public transactions.
  • Marvell Technology in connection with multiple transactions, including its acquisition of Tanzanite Silicon Solutions.
  • Coda in connection with its acquisition by Grammarly.
  • Beacon Platform in connection with its acquisition by Clearwater Analytics.
  • Bayer AG in connection with multiple transactions, including: the divestment of Bayer's West Sacramento biologics R&D site to Ginkgo Bioworks and related multi-year strategic partnership with Ginkgo Bioworks to accelerate R&D of biologics projects for agriculture; the sale of its global vegetable seeds business to BASF (announced deal value $1.19 billion); the formation of its BlueRock Therapeutics joint venture with Versant Ventures and subsequent acquisition of BlueRock Therapeutics (announced enterprise value $1 billion); its $215 million investment in Century Therapeutics, LLC; its cumulative investment of over $50 million in One Drop as lead investor in One Drop's Series B and Series C financings; its Unfold Bio joint venture with Temasek; its Joyn Bio joint venture with Ginkgo Bioworks; its Oerth Bio joint venture with Arvinas and related investment in Arvinas; its investment in the US$45 million Series C financing of Sound Agriculture; and several other strategic investments of Leaps by Bayer in an array of emerging growth life science companies.
  • FormFactor in connection with its $100 million divestment of FRT metrology.
  • Motorola Solutions in the sale of its Enterprise Mobility business to Zebra Technologies (announced deal value US$3.45 billion) (international aspects only) and certain other confidential non-public transactions.
  • Zynga in its $250 million acquisition of Chartboost.
  • Luminar Technologies in connection with its acquisitions of Freedom Photonics and Civil Maps.
  • Maxim Integrated Products in its acquisitions of Trinamic Motion Control BmBH and Icron Technologies; the sale of its MEMs business to Hanking Industrial; the sale/outsourcing of its manufacturing facility in San Antonio to TowerJazz; the sale of its smart meter/energy monitoring business to Silergy; the sale of its capacitive touch business to Qualcomm; and several other confidential non-public transactions.
  • Agilent Technologies in its spinoff of its electronic measurement business (known as Keysight Technologies).
  • NetScout Systems in connection with its acquisition of Danaher’s communication business (announced deal value US$2.6 billion) (international aspects only).
  • Symantec Corporation in the sale of its information management business (dba “Veritas”) to The Carlyle Group (announced deal value US$8 billion) (international aspects only).

Practice:

  • Mergers & Acquisitions

Ramy Shweiky Partner

San Francisco

Ramy advises public and private companies and their financial sponsors in the technology and life sciences sectors on complex, strategic transactions, including cross-border M&A, joint ventures, and multi-jurisdictional carve-outs. He also counsels boards and investors on fiduciary duties and other corporate governance matters.

Ramy is a member of the board of directors of Crisis Text Line, a global not-for-profit organization providing free mental health texting service. He has been recognized as a "Rising Star" in M&A by Super Lawyers.

Select Transactions

  • Workday in connection with multiple transactions, including its pending acquisitions of Sana Labs and Paradox, and its acquisitions of Flowise, Evisort, HiredScore, VNDLY, Peakon and Zimit.
  • Trimble in connection with its sale of Spatial Dimension to an affiliate of Vela Software, its global divestment of four businesses to The Jordan Company, and its acquisition of several software companies, including: StructShare, Bilberry, Azteca Systems LLC (dba “Cityworks”); Vianova Systems AS; Nexala Ltd.; Manhattan Software Group Ltd.; and certain other confidential non-public transactions.
  • Marvell Technology in connection with multiple transactions, including its acquisition of Tanzanite Silicon Solutions.
  • Coda in connection with its acquisition by Grammarly.
  • Beacon Platform in connection with its acquisition by Clearwater Analytics.
  • Bayer AG in connection with multiple transactions, including: the divestment of Bayer's West Sacramento biologics R&D site to Ginkgo Bioworks and related multi-year strategic partnership with Ginkgo Bioworks to accelerate R&D of biologics projects for agriculture; the sale of its global vegetable seeds business to BASF (announced deal value $1.19 billion); the formation of its BlueRock Therapeutics joint venture with Versant Ventures and subsequent acquisition of BlueRock Therapeutics (announced enterprise value $1 billion); its $215 million investment in Century Therapeutics, LLC; its cumulative investment of over $50 million in One Drop as lead investor in One Drop's Series B and Series C financings; its Unfold Bio joint venture with Temasek; its Joyn Bio joint venture with Ginkgo Bioworks; its Oerth Bio joint venture with Arvinas and related investment in Arvinas; its investment in the US$45 million Series C financing of Sound Agriculture; and several other strategic investments of Leaps by Bayer in an array of emerging growth life science companies.
  • FormFactor in connection with its $100 million divestment of FRT metrology.
  • Motorola Solutions in the sale of its Enterprise Mobility business to Zebra Technologies (announced deal value US$3.45 billion) (international aspects only) and certain other confidential non-public transactions.
  • Zynga in its $250 million acquisition of Chartboost.
  • Luminar Technologies in connection with its acquisitions of Freedom Photonics and Civil Maps.
  • Maxim Integrated Products in its acquisitions of Trinamic Motion Control BmBH and Icron Technologies; the sale of its MEMs business to Hanking Industrial; the sale/outsourcing of its manufacturing facility in San Antonio to TowerJazz; the sale of its smart meter/energy monitoring business to Silergy; the sale of its capacitive touch business to Qualcomm; and several other confidential non-public transactions.
  • Agilent Technologies in its spinoff of its electronic measurement business (known as Keysight Technologies).
  • NetScout Systems in connection with its acquisition of Danaher’s communication business (announced deal value US$2.6 billion) (international aspects only).
  • Symantec Corporation in the sale of its information management business (dba “Veritas”) to The Carlyle Group (announced deal value US$8 billion) (international aspects only).
466283

Practice:

  • Compensation & Benefits

Rebecca Servian Partner

London

Her expertise includes the creation of both equity-based and cash-based incentive plans, including the full range of HMRC tax-advantaged plans such as EMI plans and CSOPs, working on the incentives aspects of corporate transactions, including both venture capital and private equity investment, public company takeovers, IPOs, and company reorganizations. She considers the impact of the transaction on the share plans for employees and implements new incentive arrangements following investment into companies and businesses. She also guides listed companies on how to reward their executive directors in accordance with market practice and best corporate governance.

Rebecca is a member of the Share Plan Lawyers Organisation and a contributor to various publications (such as the Practical Law Company). She received a band 5 ranking in Employee Share Schemes & Incentives by Chambers UK 2025, is a “Leading Individual” under The Legal 500’s legal directory and has been recognized by MergerLinks as one of the top 30 most active up-and-coming tax lawyers in EMEA.

466283

Practice:

  • Compensation & Benefits

Rebecca Servian Partner

London

Her expertise includes the creation of both equity-based and cash-based incentive plans, including the full range of HMRC tax-advantaged plans such as EMI plans and CSOPs, working on the incentives aspects of corporate transactions, including both venture capital and private equity investment, public company takeovers, IPOs, and company reorganizations. She considers the impact of the transaction on the share plans for employees and implements new incentive arrangements following investment into companies and businesses. She also guides listed companies on how to reward their executive directors in accordance with market practice and best corporate governance.

Rebecca is a member of the Share Plan Lawyers Organisation and a contributor to various publications (such as the Practical Law Company). She received a band 5 ranking in Employee Share Schemes & Incentives by Chambers UK 2025, is a “Leading Individual” under The Legal 500’s legal directory and has been recognized by MergerLinks as one of the top 30 most active up-and-coming tax lawyers in EMEA.

124435

Practice:

  • Finance Sector
  • 稅務
  • Corporate Tax
  • Mergers & Acquisitions
  • Technology Companies Group
  • Compensation & Benefits
  • Real Estate
  • Tax Advocacy
  • Energy
  • Infrastructure

Eric Wall Partner

San Francisco

Eric counsels private and public companies, including private equity funds, on the tax aspects of their most important business transactions, including domestic and cross-border mergers and acquisitions, investments, joint ventures, and restructurings. In particular, Eric has significant experience with the tax matters most critical to clients in the technology and life science sectors. Eric also has significant experience advising clients on equity and other compensation tax matters, real estate tax matters and tax controversy matters.

Eric began his career at the firm as a summer associate in 2001.

124435

Practice:

  • Finance Sector
  • 稅務
  • Corporate Tax
  • Mergers & Acquisitions
  • Technology Companies Group
  • Compensation & Benefits
  • Real Estate
  • Tax Advocacy
  • Energy
  • Infrastructure

Eric Wall Partner

San Francisco

Eric counsels private and public companies, including private equity funds, on the tax aspects of their most important business transactions, including domestic and cross-border mergers and acquisitions, investments, joint ventures, and restructurings. In particular, Eric has significant experience with the tax matters most critical to clients in the technology and life science sectors. Eric also has significant experience advising clients on equity and other compensation tax matters, real estate tax matters and tax controversy matters.

Eric began his career at the firm as a summer associate in 2001.

453686

Practice:

  • FDA & Healthcare Regulatory
  • Life Sciences & HealthTech
  • Strategic Advisory & Government Enforcement (SAGE)
  • Technology Companies Group
  • Technology & Innovation

Amy M. Joseph Partner

Boston

Amy works with digital health companies, health systems and other public and private companies—from new entrants to seasoned organizations—to address regulatory compliance and transactional needs. She also advises investors and collaborates with clients to understand their business goals and tailor practical solutions to help them achieve those objectives. Amy is well-versed in the corporate governance, data privacy, and security and scope-of-practice considerations facing the healthcare industry as it incorporates artificial intelligence (AI) and machine-learning (ML) solutions into clinical workflows. Her practice includes structuring and scaling national telehealth practices across a range of clinical disciplines, including complex collaborative arrangements involving labs, medical device manufacturers, remote patient monitoring solutions and pharmacies.

Amy spends much of her time working with clients on vetting and developing strategic affiliations, joint venture transactions and other novel business arrangements, including developing value-based enterprises and otherwise identifying means to achieve further alignment among stakeholders. She advises on reimbursement issues with respect to federal healthcare programs, private payors and self-pay business models. She also helps develop compliance programs and advises on related protocols and best practices.

In particular, Amy advises on physician self-referral, anti-kickback and other fraud and abuse law matters as well as on patient privacy matters, including HIPAA, 42 CFR Part 2 and corresponding state-level compliance. Amy also assists with internal investigations and assessing and responding to the results, including developing corrective action recommendations and self-disclosures.

A sought-after speaker and prolific writer on some of the most complex and critical issues in healthcare law, Amy shares her insights in publications and presentations across the country. She co-authored chapters in numerous publications, including the telemedicine chapter of the American Bar Association’s Physician Law: Evolving Trends & Hot Topics and a chapter addressing telehealth in the MCLE Massachusetts Health and Hospital Law Manual.

Chambers USA notes that Amy has “deep expertise in matters that impact healthcare providers and healthcare transactions,” “is a terrific resource on a range of regulatory issues” and “an expert in the Stark Law.”

Amy graduated first in her class at UCLA Law and was elected to the Order of the Coif. Prior to law school, Amy served in the U.S. Air Force.

453686

Practice:

  • FDA & Healthcare Regulatory
  • Life Sciences & HealthTech
  • Strategic Advisory & Government Enforcement (SAGE)
  • Technology Companies Group
  • Technology & Innovation

Amy M. Joseph Partner

Boston

Amy works with digital health companies, health systems and other public and private companies—from new entrants to seasoned organizations—to address regulatory compliance and transactional needs. She also advises investors and collaborates with clients to understand their business goals and tailor practical solutions to help them achieve those objectives. Amy is well-versed in the corporate governance, data privacy, and security and scope-of-practice considerations facing the healthcare industry as it incorporates artificial intelligence (AI) and machine-learning (ML) solutions into clinical workflows. Her practice includes structuring and scaling national telehealth practices across a range of clinical disciplines, including complex collaborative arrangements involving labs, medical device manufacturers, remote patient monitoring solutions and pharmacies.

Amy spends much of her time working with clients on vetting and developing strategic affiliations, joint venture transactions and other novel business arrangements, including developing value-based enterprises and otherwise identifying means to achieve further alignment among stakeholders. She advises on reimbursement issues with respect to federal healthcare programs, private payors and self-pay business models. She also helps develop compliance programs and advises on related protocols and best practices.

In particular, Amy advises on physician self-referral, anti-kickback and other fraud and abuse law matters as well as on patient privacy matters, including HIPAA, 42 CFR Part 2 and corresponding state-level compliance. Amy also assists with internal investigations and assessing and responding to the results, including developing corrective action recommendations and self-disclosures.

A sought-after speaker and prolific writer on some of the most complex and critical issues in healthcare law, Amy shares her insights in publications and presentations across the country. She co-authored chapters in numerous publications, including the telemedicine chapter of the American Bar Association’s Physician Law: Evolving Trends & Hot Topics and a chapter addressing telehealth in the MCLE Massachusetts Health and Hospital Law Manual.

Chambers USA notes that Amy has “deep expertise in matters that impact healthcare providers and healthcare transactions,” “is a terrific resource on a range of regulatory issues” and “an expert in the Stark Law.”

Amy graduated first in her class at UCLA Law and was elected to the Order of the Coif. Prior to law school, Amy served in the U.S. Air Force.

Practice:

  • Energy & Infrastructure
  • Renewable Energy
  • Offshore Wind
  • Wind Energy
  • Solar Energy
  • Hydrogen
  • Energy Storage
  • Mergers & Acquisitions
  • Responsible Business

David O'Donovan Managing Associate

London

David's experience primarily includes renewable energy projects (onshore and offshore wind, solar PV, energy-from-waste and green hydrogen) and other energy transition projects (including carbon capture, usage and storage) with a particular focus on M&A, joint ventures and project development. He also has experience advising on governance, regulatory and ESG-related matters.

Practice:

  • Energy & Infrastructure
  • Renewable Energy
  • Offshore Wind
  • Wind Energy
  • Solar Energy
  • Hydrogen
  • Energy Storage
  • Mergers & Acquisitions
  • Responsible Business

David O'Donovan Managing Associate

London

David's experience primarily includes renewable energy projects (onshore and offshore wind, solar PV, energy-from-waste and green hydrogen) and other energy transition projects (including carbon capture, usage and storage) with a particular focus on M&A, joint ventures and project development. He also has experience advising on governance, regulatory and ESG-related matters.